Wyatt technology announces breakthrough in Field Flow Fractionation (FFF) separation technology

Wyatt Technology, the world leader in instrumentation for absolute macromolecular and nanoparticle characterization, reveals the launch of its 6th-generation Eclipse™ FFF system that represents an entirely new paradigm of FFF technology.

This completely new line of separation instrumentation and software was designed for the widest range of analytes including proteins, polymers, viruses, gene vectors, liposomal drug nanoparticles, and more. Covering a range of sizes from 1 nm to 10 μm, the Eclipse offers programmable separation power for enhanced resolution within any size range. The system incorporates sophisticated micro-controllers and sensors with built-in intelligence and an intuitive interface to ensure simple use, reliability and repeatability across research, development and quality control environments.

The introduction of Mobility™ implements electrical/asymmetric-flow FFF for determining size-resolved zeta potential. The new Dilution Control Module™ (DCM) increases sample concentrations up to 10x, for higher sensitivity and fraction titer. Improved channel design provides unique and accurate temperature control for higher sample recovery, reproducibility and pressure stability.

To say that I’m proud of the accomplishments of Team Wyatt in developing the new Eclipse and Mobility hardware products, and VISION software package would be an understatement. Add in the complexities of coordinating so many contributors during a pandemic and we have an extraordinary story on our hands. The complete execution of a product redesign is difficult enough under ordinary circumstances, but in this case it was re-imagining of what FFF is and how it can be made more accessible to more scientists. The resulting products, their novelty and their utility move FFF from a relatively obscure area of separation science into the mainstream.”

Geofrey Wyatt, CEO, Wyatt Technology

Developing reliable means of separation and characterization methods is just one more way that Wyatt Technology fulfills its mission: to help ensure our customers’ success in providing leading-edge, life-enhancing products. Additional information on these groundbreaking instruments is found at https://www.wyatt.com/separation.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Waters | Wyatt Technology. (2022, June 28). Wyatt technology announces breakthrough in Field Flow Fractionation (FFF) separation technology. News-Medical. Retrieved on December 03, 2024 from https://www.news-medical.net/news/20201021/Wyatt-technology-announces-breakthrough-in-Field-Flow-Fractionation-(FFF)-separation-technology.aspx.

  • MLA

    Waters | Wyatt Technology. "Wyatt technology announces breakthrough in Field Flow Fractionation (FFF) separation technology". News-Medical. 03 December 2024. <https://www.news-medical.net/news/20201021/Wyatt-technology-announces-breakthrough-in-Field-Flow-Fractionation-(FFF)-separation-technology.aspx>.

  • Chicago

    Waters | Wyatt Technology. "Wyatt technology announces breakthrough in Field Flow Fractionation (FFF) separation technology". News-Medical. https://www.news-medical.net/news/20201021/Wyatt-technology-announces-breakthrough-in-Field-Flow-Fractionation-(FFF)-separation-technology.aspx. (accessed December 03, 2024).

  • Harvard

    Waters | Wyatt Technology. 2022. Wyatt technology announces breakthrough in Field Flow Fractionation (FFF) separation technology. News-Medical, viewed 03 December 2024, https://www.news-medical.net/news/20201021/Wyatt-technology-announces-breakthrough-in-Field-Flow-Fractionation-(FFF)-separation-technology.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Stability Testing of Therapeutic Proteins using DLS and Machine Learning